Equities Analysts Offer Predictions for YMAB FY2025 Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Cantor Fitzgerald lowered their FY2025 earnings estimates for Y-mAbs Therapeutics in a research note issued on Wednesday, March 5th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings per share of ($0.92) for the year, down from their prior forecast of ($0.67). The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.65) per share.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The business had revenue of $26.50 million for the quarter, compared to analyst estimates of $26.70 million. During the same period in the prior year, the company earned ($0.02) EPS.

Other research analysts have also issued reports about the stock. Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a research report on Thursday, December 5th. They set a “buy” rating and a $17.00 target price on the stock. Morgan Stanley lowered their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a report on Wednesday. Oppenheimer started coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They set an “outperform” rating and a $23.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Y-mAbs Therapeutics in a report on Monday, January 13th. Finally, Truist Financial dropped their price target on Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.30.

Y-mAbs Therapeutics Stock Down 1.7 %

NASDAQ:YMAB opened at $5.16 on Friday. Y-mAbs Therapeutics has a fifty-two week low of $4.25 and a fifty-two week high of $18.10. The firm’s fifty day simple moving average is $6.28 and its 200-day simple moving average is $10.47. The stock has a market cap of $231.11 million, a PE ratio of -9.56 and a beta of 0.65.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Y-mAbs Therapeutics during the third quarter worth about $44,000. KLP Kapitalforvaltning AS acquired a new stake in Y-mAbs Therapeutics during the fourth quarter worth approximately $46,000. ProShare Advisors LLC purchased a new stake in Y-mAbs Therapeutics in the 4th quarter worth approximately $99,000. Intech Investment Management LLC acquired a new position in Y-mAbs Therapeutics in the 3rd quarter valued at $133,000. Finally, Wells Fargo & Company MN raised its holdings in Y-mAbs Therapeutics by 54.1% in the 4th quarter. Wells Fargo & Company MN now owns 17,458 shares of the company’s stock valued at $137,000 after acquiring an additional 6,131 shares during the last quarter. Institutional investors and hedge funds own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.